Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
新型三聚体 HIV-1 Env 免疫原的结构和免疫原性
基本信息
- 批准号:9927056
- 负责人:
- 金额:$ 81.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-19 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcquired Immunodeficiency SyndromeAnimalsAntibody FormationAntibody ResponseAntigensBinding SitesBiological AssayComplexComputer SimulationCryoelectron MicroscopyDNADental crownsDevelopmentEngineeringEpitopesExtracellular DomainGenerationsGlycoproteinsGoalsHIVHIV Envelope Protein gp120HIV vaccineHIV-1ImageryImmuneImmunizeImmunologicsIndividualMacaca mulattaMasksMolecular ConformationOryctolagus cuniculusPolysaccharidesPropertyProtein EngineeringProteinsRegimenResolutionScaffolding ProteinSiteSpecificityStructureTestingVaccine DesignVaccinesWorkbasedesignimmunogenicimmunogenicityimprovedinfection riskneutralizing antibodynovelnovel strategiespandemic diseasescaffoldsuccesstrimer corevaccine developmentvirus envelope
项目摘要
A vaccine is needed to stop the HIV-1/AIDS pandemic, however, the development of a protective vaccine
remains a great challenge and requires novel strategies. Various approaches to stabilize the whole
extracellular domain of the HIV-1 envelope (Env) has led to greatly improved vaccine designs, e.g., the
development of the SOSIP trimer, which, in addition to having provided a refined structural understanding of
the Env trimer, is considered as a promising immunogen because it harbors all the known vulnerable sites on
the Env trimer targeted by bnAbs. However, SOSIP-based immunogens have achieved only limited success
due to unwanted distracting epitope sites that divert Ab responses to strain-specific ones. Unlike whole Env
extracellular domain approaches, we have been using a divide-and-conquer strategy by starting with individual
domains of the Env trimer to develop domain-specific immunogens which have the advantage of immune-
focusing Ab responses to selected Env domains and epitopes and of avoiding induction of Abs to unwanted
epitope regions. We started with the V1V2 domain, not only for its domain structure spatially located at the Env
apex but also its Abs inversely correlate with the risk of infection in the RV144 trial, have developed a panel of
trimeric V1V2 domain immunogens by scaffolding V1V2 of gp120 on trimeric non-HIV proteins, and
demonstrated that they can induce V1V2-focused Ab responses. Moreover, further design efforts have resulted
in a single chain tandem V1V2 trimer showing antigenic reactivity with trimer-specific bnAbs. We hypothesize
that such V1V2-domain immunogens can be improved to present the native Env apex configuration by further
structural characterization and engineering. To expand from the Env apex, we have then designed a ‘re-cored’
Env trimer immunogen by replacing the gp120 inner domain and gp41 in the prefusion trimer structure with a
stable trimeric non-HIV scaffold protein; antigenicity tests demonstrated that this molecule harbors all key bnAb
binding sites of the trimeric Env apex and EM visualization showed it to have a well-formed trimeric
configuration. This novel construct provides a starting point to develop a trimeric immunogen that carries key
vulnerable sites of the Env trimer which could become an attractive alternative to the SOSIP trimers, offering
greater focus on the most promising bnAb epitopes. The goal of this R01 project is to structurally characterize
these rationally-designed immunogens and further apply our structure-based platform to develop new
generations of them so that they serve as effective immunogens targeting native trimeric configurations. We
have three Aims. 1) Characterize and refine the trimeric V1V2-scaffold constructs mimicking the native
prefusion conformation of the Env trimer apex. 2) Develop the re-cored Env trimer immunogen harboring key
bnAb sites. 3) Test the immunogenicity of these refined immunogens in animals. At the completion of this
project, our novel trimeric immunogens will be fully characterized and selected native-like immunogens can
then be move forward in the pipeline for vaccine development and for NHP challenge studies.
需要一种疫苗来阻止HIV-1/艾滋病的流行,然而,
仍然是一个巨大的挑战,需要新的战略。多种方式稳定整体
HIV-1包膜的细胞外结构域(Env)已经导致大大改进的疫苗设计,例如,的
开发的SOSIP三聚体,其中,除了提供了一个完善的结构理解,
Env三聚体被认为是一种有前途的免疫原,因为它含有所有已知的脆弱位点,
bnAb靶向的Env三聚体。然而,基于SOSIP的免疫原只取得了有限的成功
这是由于不需要的分散表位位点将Ab应答转移到菌株特异性应答。与整个环境不同
细胞外结构域的方法,我们一直在使用分而治之的策略,从个人开始,
Env三聚体的结构域,以开发具有免疫-
将Ab应答集中于选定的Env结构域和表位,并避免将Ab诱导至不需要的
表位区。我们从V1 V2结构域开始,不仅因为其结构域结构空间上位于Env
在RV 144试验中,apex及其Abs与感染风险呈负相关,已经开发了一组
- 通过在三聚体非HIV蛋白上支架化gp 120的V1 V2的三聚体V1 V2结构域免疫原,和
证明它们可以诱导V1 V2聚焦的Ab应答。此外,进一步的设计工作也导致了
在单链串联V1 V2三聚体中显示与三聚体特异性bnAb的抗原反应性。我们假设
这样的V1 V2-结构域免疫原可以被改进以呈现天然Env顶点构型,
结构表征和工程。为了从Env顶点扩展,我们设计了一个“重新核心”
Env三聚体免疫原,通过用一个融合蛋白替代融合前三聚体结构中的gp 120内部结构域和gp 41,
稳定的三聚体非HIV支架蛋白;抗原性试验证明该分子含有所有关键bnAb
三聚体Env顶端的结合位点和EM可视化显示其具有良好形成的三聚体
配置.这种新的构建体提供了一个起点,以开发一种三聚体免疫原,
Env三聚体的脆弱位点,其可以成为SOSIP三聚体的有吸引力的替代物,
更多地关注最有前途的bnAb表位。本R 01项目的目标是在结构上表征
这些合理设计的免疫原,并进一步应用我们的基于结构的平台来开发新的
因此,它们可以作为靶向天然三聚体构型的有效免疫原。我们
有三个目标。1)表征和改进模拟天然V1 V2-支架的三聚体V1 V2-支架构建体,
Env三聚体顶端的融合前构象。2)开发具有密钥的重新核心的Env三聚体免疫原
bnAb位点。3)在动物中测试这些精制免疫原的免疫原性。在完成这一
项目,我们的新的三聚体免疫原将充分表征和选择的天然样免疫原可以
然后在疫苗开发和NHP挑战研究的管道中向前推进。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIANGPENG KONG其他文献
XIANGPENG KONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIANGPENG KONG', 18)}}的其他基金
Immunogenicity of the newly identified V3 crown vulnerable site
新发现的 V3 冠脆弱位点的免疫原性
- 批准号:
10548294 - 财政年份:2022
- 资助金额:
$ 81.36万 - 项目类别:
Immunogenicity of the newly identified V3 crown vulnerable site
新发现的 V3 冠脆弱位点的免疫原性
- 批准号:
10659226 - 财政年份:2022
- 资助金额:
$ 81.36万 - 项目类别:
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
新型三聚体 HIV-1 Env 免疫原的结构和免疫原性
- 批准号:
10020934 - 财政年份:2019
- 资助金额:
$ 81.36万 - 项目类别:
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
新型三聚体 HIV-1 Env 免疫原的结构和免疫原性
- 批准号:
10677620 - 财政年份:2019
- 资助金额:
$ 81.36万 - 项目类别:
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
新型三聚体 HIV-1 Env 免疫原的结构和免疫原性
- 批准号:
10229479 - 财政年份:2019
- 资助金额:
$ 81.36万 - 项目类别:
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
新型三聚体 HIV-1 Env 免疫原的结构和免疫原性
- 批准号:
10458575 - 财政年份:2019
- 资助金额:
$ 81.36万 - 项目类别:
Rational Design of Immunogens Targeting HIV-1 Quaternary Neutrlizing Epitopes
针对 HIV-1 四级中和表位的免疫原的合理设计
- 批准号:
8789433 - 财政年份:2014
- 资助金额:
$ 81.36万 - 项目类别:
Epitope-targeted Vaccines for HIV-1 Prevention
用于预防 HIV-1 的表位靶向疫苗
- 批准号:
8789431 - 财政年份:2014
- 资助金额:
$ 81.36万 - 项目类别:
Epitope-targeted Vaccines for HIV-1 Prevention
用于预防 HIV-1 的表位靶向疫苗
- 批准号:
8301820 - 财政年份:2012
- 资助金额:
$ 81.36万 - 项目类别:
Epitope-targeted Vaccines for HIV-1 Prevention
用于预防 HIV-1 的表位靶向疫苗
- 批准号:
8706786 - 财政年份:2012
- 资助金额:
$ 81.36万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 81.36万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 81.36万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 81.36万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 81.36万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 81.36万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 81.36万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 81.36万 - 项目类别: